Table 3.

Univariable and multivariable analysis for risk factors for CKD at 1 year

Variable	Univariable analysisOR (95% CI)	P-value	Multivariable analysisOR (95% CI)	P-value
Age at transplant	1.09 (1.05–1.13)	<0.0001	1.09 (1.05–1.14)	<0.0001
Female gender	2.01 (1.05–3.88)	0.04	2.83 (1.34–5.97)	0.006
Hypertension	2.02 (1.05–3.89)	0.04
Diabetes	2.51 (0.98–6.41)	0.05	1.63 (0.58–4.56)	0.35
Baseline eGFR	0.91 (0.89–0.94)	<0.0001
AKI within 100 days post-transplant	2.95 (1.41–6.16)	0.004	3.86 (1.70–8.73)	0.001
Transplant regimen (MAC versus RIC)	0.37 (0.14–0.99)	0.05
GVHD prophylaxis (ATG-PTCy-CSA versus others)	0.91 (0.47–1.78)	0.79
aGVHD (grade 3–4)	0.53 (0.15–1.87)	0.32
cGVHD (moderate/severe)	1.17 (0.58–2.34)	0.66	1.31 (0.60–2.84)	0.50

Univariable and multivariable logistic regression results are presented. Patients who died within 1 year post-transplant were removed from analyses. Due to lack of power, only five variables were included in the multivariable model to avoid over-fit. For this reason, hypertension and baseline eGFR were excluded from the model. Diabetes was included in the model as it is a recognized major risk factor for CKD. We also retained cGVHD in the model (although nonsignificant in univariate analysis), as cGVHD has been reported as a significant risk factor for kidney disease after transplantation in multiple recent studies [19–21]. Alternative multivariate model incorporating baseline eGFR and using only variables with the lowest P-value in univariate analysis is provided as Supplementary material.

OR = odds ratio; CKD = chronic kidney disease; AKI = acute kidney injury; MAC = myeloablative conditioning; RIC = reduced intensity regimen; GVHD = graft-versus-host disease; ATG-PTCy-CSA = anti-thymocyte globulin with post-transplant cyclophosphamide and cyclosporine; aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease.